文献速递流行病学与生物统计基础与转化研究

衣原体和淋球菌感染筛查:USPSTF更新证据报告与系统综述

Screening for Chlamydial and Gonococcal Infections: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
PubMed 文献 · JAMA · 2021-01-01

研究发现年轻女性衣原体筛查与降低盆腔炎风险相关,风险预测工具除年龄外准确性有限,多数解剖部位检测准确性高。男性及孕期筛查有效性、最佳筛查间隔和筛查危害需进一步评估。

要点

  • 年轻女性衣原体筛查与降低盆腔炎风险相关。
  • 风险预测工具除年龄外准确性有限。
  • 多数解剖部位衣原体和淋球菌检测准确性高。

核心结论

  • 衣原体筛查与年轻女性盆腔炎风险降低显著相关。
  • 风险预测标准除年龄外准确性有限。
  • 无症状衣原体和淋球菌感染检测在多数解剖部位高度准确,包括尿液和自采标本。
  • 男性及孕期筛查有效性、最佳筛查间隔和筛查不良效应需进一步评估。

研究设计与样本

  • 检索Cochrane Central Register of Controlled Trials、Cochrane Database of Systematic Reviews和Ovid MEDLINE(2014年1月1日至2020年5月28日),监测至2021年5月21日。
  • 由一名研究者提取数据、另一名核对准确性,两名研究者独立评估研究质量。

主要发现

  • 在4项试验中的2项,衣原体筛查相比不筛查与盆腔炎风险降低显著相关。
  • 最大试验中,衣原体筛查与医院诊断的盆腔炎减少相关(0.24% vs 0.38%;相对风险0.6 [95% CI, 0.4-1.0]),但与门诊诊断的盆腔炎或附睾炎无关。
  • 无症状女性风险预测工具研究中,年龄小于22岁与广泛标准准确性相当。
  • 女性衣原体检测敏感性:宫颈内膜89%-100%,自采和医生采集阴道90%-100%;男性:尿道口100%、尿道99%、直肠92%,但男男性行为者咽部较低(69.2%)。
  • 淋球菌检测敏感性在所有解剖样本中为89%或更高;各解剖部位和采集方法的假阳性和假阴性率低。

临床怎么用

  • 支持对无症状性活跃年轻女性(≤24岁)及感染风险较高的年长女性进行衣原体筛查。
  • 年龄小于22岁可作为无症状女性风险预测的简化标准。
  • 尿液和自采标本可用于衣原体和淋球菌检测,多数解剖部位准确性高。
  • 男性及孕期筛查的有效性证据不足,需个体化决策。

局限性

  • 男性筛查有效性证据不足。
  • 孕期筛查有效性证据不足。
  • 最佳筛查间隔未明确。
  • 筛查不良效应需进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The 2014 US Preventive Services Task Force (USPSTF) recommendation statement supported the effectiveness of screening for chlamydia and gonorrhea in asymptomatic, sexually active women 24 years or younger and in older women at increased risk for infection, although evidence for screening in men was insufficient. OBJECTIVE: To update the 2014 USPSTF review on screening for chlamydial and gonococcal infection in adults and adolescents, including those who are pregnant. DATA SOURCES: Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Ovid MEDLINE (January 1, 2014, through May 28, 2020) with surveillance through May 21, 2021. STUDY SELECTION: Randomized clinical trials and observational studies of screening effectiveness, accuracy of risk stratification and alternative screening methods, accuracy of tests, and screening harms. DATA EXTRACTION AND SYNTHESIS: One investigator abstracted data; a second checked accuracy. Two investigators independently assessed study quality. MAIN OUTCOMES AND MEASURES: Complications of infection; infection transmission or acquisition; diagnostic accuracy of anatomical site-specific testing and collection methods; screening harms. RESULTS: Twenty-seven studies were included (N = 179 515). Chlamydia screening compared with no screening was significantly associated with reduced risk of pelvic inflammatory disease (PID) in 2 of 4 trials and with reduced hospital-diagnosed PID (0.24% vs 0.38%); relative risk, 0.6 [95% CI, 0.4-1.0]), but not clinic-diagnosed PID or epididymitis, in the largest trial. In studies of risk prediction instruments in asymptomatic women, age younger than 22 years demonstrated comparable accuracy to extensive criteria. Sensitivity of chlamydial testing was similar at endocervical (89%-100%) and self- and clinician-collected vaginal (90%-100%) sites for women and at meatal (100%), urethral (99%), and rectal (92%) sites for men but lower at pharyngeal sites (69.2%) for men who have sex with men. Sensitivity of gonococcal testing was 89% or greater for all anatomical samples. False-positive and false-negative testing rates were low across anatomical sites and collection methods. CONCLUSIONS AND RELEVANCE: Screening for chlamydial infection was significantly associated with a lower risk of PID in young women. Risk prediction criteria demonstrated limited accuracy beyond age. Testing for asymptomatic chlamydial and gonococcal infections was highly accurate at most anatomical sites, including urine and self-collected specimens. Effectiveness of screening in men and during pregnancy, optimal screening intervals, and adverse effects of screening require further evaluation.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Cantor A, Dana T, Griffin JC, et al. Screening for Chlamydial and Gonococcal Infections: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021. PMID: 34519797. doi:10.1001/jama.2021.10577

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。